Melanocortins protect against multiple organ dysfunction syndrome in mice

British Journal of Pharmacology

Volumn 162, Issue 4, 2011, Pages 917-928

  Bitto, Alessandra ^a   Polito, Francesca ^a   Altavilla, Domenica ^a   Irrera, Natasha ^a   Giuliani, Daniela ^b   Ottani, Alessandra ^b   Minutoli, Letteria ^a   Spaccapelo, Luca ^b   Galantucci, Maria ^b   Lodi, Renzo ^b   Guzzo, Giuseppe ^a   Guarini, Salvatore ^b   Squadrito, Francesco ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

cholinergic anti inflammatory pathway; melanocortin peptides; mouse; multiple organ dysfunction syndrome; nicotinic acetylcholine receptors

Indexed keywords

ALPHA INTERMEDIN; CHLORISONDAMINE; INTERLEUKIN 10; MELANOCORTIN; MELANOCORTIN 4 RECEPTOR; MELANOCORTIN RECEPTOR ANTAGONIST; MESSENGER RNA; PHENYLALANINE DERIVATIVE; RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; HISTOPATHOLOGY; LIVER; LUNG; MOUSE; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; SURVIVAL RATE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT DURATION;

EID: 79251521843     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01098.x     Document Type: Article

References (60)

1. Alexander SPH, Mathie A, Peters JA, (2009). Guide to Receptors and Channels (GRAC), 4th edition. Br J Pharmacol 158 (Suppl. 1): S1-S254.
2. Altavilla D, Cainazzo MM, Squadrito F, Guarini S, Bertolini A, Bazzani C, (1998). Tumour necrosis factor-a as a target of melanocortins in haemorrhagic shock, in the anaesthetized rat. Br J Pharmacol 124: 1587-1590.
3. Altavilla D, Guarini S, Bitto A, Mioni C, Giuliani D, Bigiani A, et al. (2006). Activation of the cholinergic anti-infiammatory pathway reduces NF-kB activation, blunts TNF-α production, and protects against splanchnic artery occlusion shock. Shock 25: 500-506.
4. Banks WA, Kastin AJ, (1995). Permeability of the blood-brain barrier to melanocortins. Peptides 16: 1157-1161.
5. Baue AE, (1997). Multiple organ failure, multiple organ dysfunction syndrome and systemic inflammatory response syndrome. Why no magic bullets? Arch Surg 132: 703-707.
6. Baue AE, (2006). MOF, MODS, and SIRS: what is in a name or an acronym? Shock 26: 438-449.
7. Bazzani C, Guarini S, Botticelli AR, Zaffe D, Tomasi A, Bini A, et al. (2001). Protective effect of melanocortin peptides in rat myocardial ischemia. J Pharmacol Exp Ther 297: 1082-1087.
8. Bertuglia S, Giusti A, (2004). Influence of ACTH-(1-24) and plasma hyperviscosity on free radical production and capillary perfusion after hemorrhagic shock. Microcirculation 11: 227-238.
9. Bertolini A, Guarini S, Ferrari W, (1986a). Adrenal-independent, anti-shock effect of ACTH-(1-24) in rats. Eur J Pharmacol 122: 387-388.
10. Bertolini A, Guarini S, Rompianesi E, Ferrari W, (1986b).-MSH and other ACTH fragments improve cardiovascular function and survival in experimental hemorrhagic shock. Eur J Pharmacol 130: 19-26.
11. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, et al. (2000). Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405: 458-462.
12. Catania A, (2007). The melanocortin system in leukocyte biology. J Leukoc Biol 81: 383-392.
13. Catania A, Cutuli M, Garofalo L, Airaghi L, Valenza F, Lipton JM, et al. (2000). Plasma concentrations and anti-cytokine effects of α-melanocyte stimulating hormone in septic patients. Crit Care Med 28: 1403-1407.
14. Catania A, Gatti S, Colombo G, Lipton JM, (2004). Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev 56: 1-29.
15. Cohen J, (2002). The immunopathogenesis of sepsis. Nature 420: 885-891.
16. Corander MP, Fenech M, Coll AP, (2009). Science of self-preservation: how melanocortin action in the brain modulates body weight, blood pressure, and ischemic damage. Circulation 120: 2260-2268.
17. Cui X, Wu R, Zhou M, Dong W, Ulloa L, Yang H, et al. (2005). Adrenomedullin and its binding protein attenuate the proinflammatory response after hemorrhage. Crit Care Med 33: 391-398.
18. Cuzzocrea S, McDonald MC, Mazzon E, Filipe HM, Centorrino T, Lepore V, et al. (2001). Beneficial effects of tempol, a membrane-permeable radical scavenger, on the multiple organ failure induced by zymosan in the rat. Crit Care Med 29: 102-111.
19. Dewar D, Moore FA, Moore EE, Balogh Z, (2009). Postinjury multiple organ failure. Injury 40: 912-918.
20. Getting SJ, (2006). Targeting melanocortin receptors as potential novel therapeutics. Pharmacol Ther 111: 1-15.
21. Phe7]α- melanocyte-stimulating hormone for long-lasting protection against ischemic stroke, in Mongolian gerbils. Eur J Pharmacol 538: 48-56.
22. Giuliani D, Mioni C, Altavilla D, Leone S, Bazzani C, Minutoli L, et al. (2006b). Both early and delayed treatment with melanocortin 4 receptor-stimulating melanocortins produces neuroprotection in cerebral ischemia. Endocrinology 147: 1126-1135.
23. Giuliani D, Mioni C, Bazzani C, Zaffe D, Botticelli AR, Capolongo S, et al. (2007). Selective melanocortin MC4 receptor agonists reverse haemorrhagic shock and prevent multiple organ damage. Br J Pharmacol 150: 595-603.
24. Giuliani D, Ottani A, Minutoli L, Di Stefano V, Galantucci M, Bitto A, et al. (2009). Functional recovery after delayed treatment of ischemic stroke with melanocortins is associated with overexpression of the activity-dependent gene Zif268. Brain Behav Immun 23: 844-850.
25. Giuliani D, Ottani A, Altavilla D, Bazzani C, Squadrito F, Guarini S, (2010). Melanocortins and the cholinergic anti-inflammatory pathway. In:, Catania A, (ed.). Advances in Experimental Medicine and Biology-Melanocortins, Multiple Actions and Therapeutic Potential, Vol. 681. Landes Bioscience and Springer Science + Business Media: Austin, TX, New York, NY, pp. 71-87.
26. Goris RJ, Boekholtz WK, van Bebber IP, Nuytinck JK, Schillings PH, (1986). Multiple-organ failure and sepsis without bacteria. An experimental model. Arch Surg 121: 897-901.
27. Guarini S, Vergoni AV, Bertolini A, (1987). Anti-shock effect of ACTH-(1-24): comparison between intracerebroventricular and intravenous route of administration. Pharmacol Res Commun 19: 255-260.
28. Guarini S, Tagliavini S, Bazzani C, Ferrari W, Bertolini A, (1990). Early treatment with ACTH-(1-24) in a rat model of hemorrhagic shock prolongs survival and extends the time-limit for blood reinfusion to be effective. Crit Care Med 18: 862-865.
29. Guarini S, Bazzani C, Mattera Ricigliano G, Bini A, Tomasi A, Bertolini A, (1996). Influence of ACTH-(1-24) on free radical levels in the blood of haemorrhage-shocked rats: direct ex vivo detection by electron spin resonance spectrometry. Br J Pharmacol 119: 29-34.
30. Guarini S, Bazzani C, Bertolini A, (1997a). Resuscitating effect of melanocortin peptides after prolonged respiratory arrest. Br J Pharmacol 121: 1454-1460.
31. Guarini S, Bini A, Bazzani C, Mattera Ricigliano G, Cainazzo MM, Tomasi A, et al. (1997b). Adrenocorticotropin normalizes the blood levels of nitric oxide in hemorrhage-shocked rats. Eur J Pharmacol 336: 15-21.
32. Guarini S, Bazzani C, Cainazzo MM, Mioni C, Ferrazza G, Vergoni AV, et al. (1999). Evidence that melanocortin 4 receptor mediates hemorrhagic shock reversal caused by melanocortin peptides. J Pharmacol Exp Ther 291: 1023-1027.
33. Guarini S, Altavilla D, Cainazzo MM, Giuliani D, Bigiani A, Marini H, et al. (2003). Efferent vagal fibre stimulation blunts NF-kB activation and protects against hypovolemic hemorrhagic shock. Circulation 107: 1189-1194.
34. Guarini S, Cainazzo MM, Giuliani D, Mioni C, Altavilla D, Marini H, et al. (2004). Adrenocorticotropin reverses hemorrhagic shock in anesthetized rats through the rapid activation of a vagal anti-inflammatory pathway. Cardiovasc Res 63: 357-365.
35. Jansen MJ, Hendriks T, Verhofstad AA, Lange W, Geeraedts LMJ, Goris RJ, (1997). Gradual development of organ damage in the murine zymosan-induced multiple organ dysfunction syndrome. Shock 8: 261-267.
36. Jochem J, (2004). Involvement of proopiomelanocortin-derived peptides in endogenous central istamine-induced reversal of critical haemorrhagic hypotension in rats. J Physiol Pharmacol 55: 57-71.
37. Lipton JM, Ceriani G, Macaluso A, McCoy D, Carnes K, Biltz J, et al. (1994). Antiinflammatory effects of the neuropeptide α-MSH in acute, chronic, and systemic inflammation. Ann NY Acad Sci 741: 137-148.
38. Magnoni S, Stocchetti N, Colombo G, Carlin A, Colombo A, Lipton JM, et al. (2003). α-Melanocyte-stimulating hormone is decreased in plasma of patients with acute brain injury. J Neurotrauma 20: 251-260.
39. van Meurs M, Wulfert FM, Knol AJ, De Haes A, Houwertjes M, Aarts LP, et al. (2008). Early organ-specific endothelial activation during hemorrhagic shock and resuscitation. Shock 29: 291-299.
40. Mioni C, Bazzani C, Giuliani D, Altavilla D, Leone S, Ferrari A, et al. (2005). Activation of an efferent cholinergic pathway produces strong protection against myocardial ischemia/reperfusion injury in rats. Crit Care Med 33: 2621-2628.
41. Noera G, Lamarra M, Guarini S, Bertolini A, (2001). Survival rate after early treatment for acute type-A aortic dissection with ACTH-(1-24). Lancet 358: 469-470.
42. Ottani A, Giuliani D, Mioni C, Galantucci M, Minutoli L, Bitto A, et al. (2009). Vagus nerve mediates the protective effects of melanocortins against cerebral and systemic damage after ischemic stroke. J Cereb Blood Flow Metab 29: 512-523.
43. Ottani A, Giuliani D, Galantucci M, Spaccapelo L, Novellino E, Grieco P, et al. (2010). Melanocortins counteract inflammatory and apoptotic responses to prolonged myocardial ischemia/reperfusion through a vagus nerve-mediated mechanism. Eur J Pharmacol 637: 124-130.
44. Redl H, Gasser H, Schlag G, Marzi I, (1993). Involvement of oxygen radicals in shock related cell injury. Br Med Bull 49: 556-565.
45. Rosas-Ballina M, Tracey KJ, (2009). Cholinergic control of inflammation. J Intern Med 265: 663-679.
46. Schlag G, Redl H, Hallström S, (1991). The cell in shock: the origin of multiple organ failure. Resuscitation 21: 137-180.
47. Seekamp AJ, Jochum M, Ziegler M, Micheal M, Gerd R, (1998). Cytokine and adhesion molecules in elective and accidental trauma-related ischaemia/reperfusion. J Trauma 44: 874-882.
48. Simons RK, Hoyt DB, Winchell RJ, Rose RM, Holbrook T, (1996). Elevated selectin levels after severe trauma: a marker for sepsis and organ failure and a potential target for immunomodulatory therapy. J Trauma 41: 653-662.
49. Squadrito F, Guarini S, Altavilla D, Squadrito G, Campo GM, Arlotta M, et al. (1999). Adrenocorticotropin reverses vascular dysfunction and protects against splanchnic artery occlusion shock. Br J Pharmacol 128: 816-822.
50. Tilney NL, Bailey GL, Morgan AP, (1973). Sequential system failure after rupture of abdominal aortic aneurysms: an unsolved problem in postoperative care. Ann Surg 178: 117-122.
51. Todd SR, Kao LS, Catania A, Mercer DW, Adams SD, Moore FA, (2009). α-Melanocyte stimulating hormone in critically injured trauma patients. J Trauma 66: 465-469.
52. Tracey KJ, (2002). The inflammatory reflex. Nature 420: 853-859.
53. Tracey KJ, (2007). Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest 117: 289-296.
54. Tsukamoto T, Chanthaphavong RS, Pape HC, (2010). Current theories on the pathophysiology of multiple organ failure after trauma. Injury 41: 21-26.
55. Vecsernyes M, Juhasz B, Der P, Kocsan R, Feher P, Bacskay I, et al. (2003). The administration of α-melanocyte-stimulating hormone protects the ischemic/reperfused myocardium. Eur J Pharmacol 470: 177-183.
56. Volman TJ, Goris RJ, van der Jagt M, van de Loo FA, Hendriks T, (2002). Organ damage in zymosan-induced multiple organ dysfunction syndrome in mice is not mediated by inducible nitric oxide synthase. Crit Care Med 30: 1553-1559.
57. Volman TJ, Goris RJ, van der Meer JW, Hendriks T, (2004). Tissue- and time-dependent upregulation of cytokine mRNA in a murine model for the multiple organ dysfunction syndrome. Ann Surg 240: 142-150.
58. Volman TJ, Hendriks T, Goris RJ, (2005). Zymosan-induced generalized inflammation: experimental studies into mechanisms leading to multiple organ dysfunction syndrome. Shock 23: 291-297.
59. Wheeler AP, Bernard GR, (1999). Treating patients with severe sepsis. N Engl J Med 340: 207-214.
60. Wikberg JES, Muceniece R, Mandrika I, Prusis P, Lindblom J, Post C, et al. (2000). New aspects on the melanocortins and their receptors. Pharmacol Res 42: 393-420.